FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2309145816> ?p ?o ?g. }

• W2309145816 endingPage "2436" @default.
• W2309145816 startingPage "2430" @default.
• W2309145816 abstract "In a Phase 1 trial, we evaluated the safety of AERAS-402, an adenovirus 35-vectored TB vaccine candidate expressing 3 Mycobacterium tuberculosis (Mtb) immunodominant antigens, in subjects with and without latent Mtb infection. HIV-negative, BCG-vaccinated Kenyan adults without evidence of tuberculosis, 10 QuantiFERON®-TB Gold In-Tube test (QFT-G)(−) and 10 QFT-G(+), were randomized 4:1 to receive AERAS-402 or placebo as two doses, on Days 0 and 56, with follow up to Day 182. There were no deaths, serious adverse events or withdrawals. For 1 AERAS-402 QFT-G(−) and 1 AERAS-402 QFT-G(+) subject, there were 3 self-limiting severe AEs of injection site pain: 1 after the first vaccination and 1 after each vaccination, respectively. Two additional severe AEs considered vaccine-related were reported after the first vaccination in AERAS-402 QFT-G(+) subjects: elevated blood creatine phosphokinase and neutropenia, the latter slowly improving but remaining abnormal until study end. AERAS-402 was not detected in urine or throat cultures for any subject. In intracellular cytokine staining studies, curtailed by technical issues, we saw modest CD4+ and CD8+ T cell responses to Mtb Ag85A/b peptide pools among both QFT-G(−) and (+) subjects, with trends in the CD4+ T cells suggestive of boosting after the second vaccine dose, slightly more so in QFT-G(+) subjects. CD4+ and CD8+ responses to Mtb antigen TB10.4 were minimal. Increases in Adenovirus 35 neutralizing antibodies from screening to end of study, seen in 50% of AERAS-402 recipients, were mostly minimal. This small study confirms acceptable safety and tolerability profiles for AERAS-402, in line with other Phase 1 studies of AERAS-402, now to include QFT-G(+) subjects." @default.
• W2309145816 created "2016-06-24" @default.
• W2309145816 creator A5007856969 @default.
• W2309145816 creator A5008152588 @default.
• W2309145816 creator A5021913918 @default.
• W2309145816 creator A5034781292 @default.
• W2309145816 creator A5043150960 @default.
• W2309145816 creator A5044909638 @default.
• W2309145816 creator A5050305370 @default.
• W2309145816 creator A5057250881 @default.
• W2309145816 creator A5060261035 @default.
• W2309145816 creator A5064528399 @default.
• W2309145816 creator A5069843611 @default.
• W2309145816 creator A5072617088 @default.
• W2309145816 creator A5075616056 @default.
• W2309145816 date "2016-05-01" @default.
• W2309145816 modified "2023-10-14" @default.
• W2309145816 title "Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON®-TB Gold (+) Kenyan adults without evidence of tuberculosis" @default.
• W2309145816 cites W1965443156 @default.
• W2309145816 cites W1979745197 @default.
• W2309145816 cites W1997299968 @default.
• W2309145816 cites W2040780498 @default.
• W2309145816 cites W2046730970 @default.
• W2309145816 cites W2055129955 @default.
• W2309145816 cites W2059505459 @default.
• W2309145816 cites W2117522110 @default.
• W2309145816 cites W2152554612 @default.
• W2309145816 cites W4205161959 @default.
• W2309145816 doi "https://doi.org/10.1016/j.vaccine.2016.03.069" @default.
• W2309145816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27026148" @default.
• W2309145816 hasPublicationYear "2016" @default.
• W2309145816 type Work @default.
• W2309145816 sameAs 2309145816 @default.
• W2309145816 citedByCount "11" @default.
• W2309145816 countsByYear W23091458162016 @default.
• W2309145816 countsByYear W23091458162017 @default.
• W2309145816 countsByYear W23091458162018 @default.
• W2309145816 countsByYear W23091458162019 @default.
• W2309145816 countsByYear W23091458162020 @default.
• W2309145816 countsByYear W23091458162021 @default.
• W2309145816 countsByYear W23091458162022 @default.
• W2309145816 crossrefType "journal-article" @default.
• W2309145816 hasAuthorship W2309145816A5007856969 @default.
• W2309145816 hasAuthorship W2309145816A5008152588 @default.
• W2309145816 hasAuthorship W2309145816A5021913918 @default.
• W2309145816 hasAuthorship W2309145816A5034781292 @default.
• W2309145816 hasAuthorship W2309145816A5043150960 @default.
• W2309145816 hasAuthorship W2309145816A5044909638 @default.
• W2309145816 hasAuthorship W2309145816A5050305370 @default.
• W2309145816 hasAuthorship W2309145816A5057250881 @default.
• W2309145816 hasAuthorship W2309145816A5060261035 @default.
• W2309145816 hasAuthorship W2309145816A5064528399 @default.
• W2309145816 hasAuthorship W2309145816A5069843611 @default.
• W2309145816 hasAuthorship W2309145816A5072617088 @default.
• W2309145816 hasAuthorship W2309145816A5075616056 @default.
• W2309145816 hasBestOaLocation W23091458161 @default.
• W2309145816 hasConcept C126322002 @default.
• W2309145816 hasConcept C142724271 @default.
• W2309145816 hasConcept C147483822 @default.
• W2309145816 hasConcept C159047783 @default.
• W2309145816 hasConcept C197934379 @default.
• W2309145816 hasConcept C203014093 @default.
• W2309145816 hasConcept C22070199 @default.
• W2309145816 hasConcept C2776763545 @default.
• W2309145816 hasConcept C2777975735 @default.
• W2309145816 hasConcept C2778375690 @default.
• W2309145816 hasConcept C2779078216 @default.
• W2309145816 hasConcept C2779806340 @default.
• W2309145816 hasConcept C2780868878 @default.
• W2309145816 hasConcept C2781069245 @default.
• W2309145816 hasConcept C71924100 @default.
• W2309145816 hasConceptScore W2309145816C126322002 @default.
• W2309145816 hasConceptScore W2309145816C142724271 @default.
• W2309145816 hasConceptScore W2309145816C147483822 @default.
• W2309145816 hasConceptScore W2309145816C159047783 @default.
• W2309145816 hasConceptScore W2309145816C197934379 @default.
• W2309145816 hasConceptScore W2309145816C203014093 @default.
• W2309145816 hasConceptScore W2309145816C22070199 @default.
• W2309145816 hasConceptScore W2309145816C2776763545 @default.
• W2309145816 hasConceptScore W2309145816C2777975735 @default.
• W2309145816 hasConceptScore W2309145816C2778375690 @default.
• W2309145816 hasConceptScore W2309145816C2779078216 @default.
• W2309145816 hasConceptScore W2309145816C2779806340 @default.
• W2309145816 hasConceptScore W2309145816C2780868878 @default.
• W2309145816 hasConceptScore W2309145816C2781069245 @default.
• W2309145816 hasConceptScore W2309145816C71924100 @default.
• W2309145816 hasFunder F4320311178 @default.
• W2309145816 hasIssue "21" @default.
• W2309145816 hasLocation W23091458161 @default.
• W2309145816 hasLocation W23091458162 @default.
• W2309145816 hasOpenAccess W2309145816 @default.
• W2309145816 hasPrimaryLocation W23091458161 @default.
• W2309145816 hasRelatedWork W13777425 @default.
• W2309145816 hasRelatedWork W1969822700 @default.
• W2309145816 hasRelatedWork W2025404538 @default.
• W2309145816 hasRelatedWork W2058168006 @default.
• W2309145816 hasRelatedWork W2118252327 @default.
• W2309145816 hasRelatedWork W2154239844 @default.

• next